Brendan P. Eckelman, Ph.D.

Brendan P. Eckelman, Ph.D.

Former Chief Scientific OfficeratInhibrx Biosciences· In proxies 2023–2024

Pay in FY2024+81% from the year before

Brendan P. Eckelman, Ph.D. was paid $2.6M in FY2024 (Dec), up 81%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Inhibrx Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Inhibrx BiosciencesPublic company · 3 yr
    • Former Chief Scientific Officer2023 – Present · 3 yrStock in role +351%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?